These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 9109387)

  • 1. Photoactivation of the nitric oxide donor SIN-1.
    Ullrich T; Oberle S; Abate A; Schröder H
    FEBS Lett; 1997 Apr; 406(1-2):66-8. PubMed ID: 9109387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxygen and oxidation promote the release of nitric oxide from sydnonimines.
    Bohn H; Schönafinger K
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S6-12. PubMed ID: 2484701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the mechanism of NO release from sydnonimines.
    Feelisch M; Ostrowski J; Noack E
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S13-22. PubMed ID: 2484692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An impurity present in some samples of SIN-1 oxidizes it to nitric oxide in anaerobic solutions.
    Wang Y; Rochelle LG; Kruszyna H; Kruszyna R; Smith RP; Wilcox DE
    Toxicology; 1994 Mar; 88(1-3):165-76. PubMed ID: 8160198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nitric oxide donor SIN-1 protects endothelial cells from tumor necrosis factor-alpha-mediated cytotoxicity: possible role for cyclic GMP and heme oxygenase.
    Polte T; Oberle S; Schröder H
    J Mol Cell Cardiol; 1997 Dec; 29(12):3305-10. PubMed ID: 9441836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular aspects underlying the vasodilator action of molsidomine.
    Noack E; Feelisch M
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S1-5. PubMed ID: 2484685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Morpholino-sydnonimine-induced suppression of human neutrophil degranulation is not mediated by cyclic GMP, nitric oxide or peroxynitrite: inhibition of the increase in intracellular free calcium concentration by N-morpholino-iminoacetonitrile, a metabolite of 3-morpholino-sydnonimine.
    Kankaanranta H; Knowles RG; Vuorinen P; Kosonen O; Holm P; Moilanen E
    Mol Pharmacol; 1997 May; 51(5):882-8. PubMed ID: 9145927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancreatic islet cells are highly susceptible towards the cytotoxic effects of chemically generated nitric oxide.
    Kröncke KD; Brenner HH; Rodriguez ML; Etzkorn K; Noack EA; Kolb H; Kolb-Bachofen V
    Biochim Biophys Acta; 1993 Sep; 1182(2):221-9. PubMed ID: 8395219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulatory and inhibitory action of nitric oxide donor agents vs. nitrovasodilators on reactive oxygen production by isolated polymorphonuclear leukocytes.
    Pieper GM; Clarke GA; Gross GJ
    J Pharmacol Exp Ther; 1994 May; 269(2):451-6. PubMed ID: 8182511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a nitric oxide donor on behavior and interaction with nitrous oxide in the mouse light/dark exploration test.
    Li S; Quock RM
    Eur J Pharmacol; 2002 Jun; 447(1):75-8. PubMed ID: 12106805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxations to SIN-1, nitric oxide, and sodium nitroprusside in canine arteries and veins.
    Miller VM; Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S67-71. PubMed ID: 2484703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of L-arginine and SIN-1 on sleep and waking in the rat during both phases of the light-dark cycle.
    Monti JM; Jantos H
    Life Sci; 2004 Sep; 75(17):2027-34. PubMed ID: 15312747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction.
    Stief CG; Holmquist F; Djamilian M; Krah H; Andersson KE; Jonas U
    J Urol; 1992 Nov; 148(5):1437-40. PubMed ID: 1433545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors.
    Singh RJ; Hogg N; Joseph J; Konorev E; Kalyanaraman B
    Arch Biochem Biophys; 1999 Jan; 361(2):331-9. PubMed ID: 9882464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of linsidomine chlorhydrate, a direct nitric oxide donor, in the treatment of human erectile dysfunction: results of a double-blind cross over trial.
    Wegner HE; Knispel HH; Klän R; Miller K
    Int J Impot Res; 1995 Dec; 7(4):233-7. PubMed ID: 8770666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The survival of skeletal muscle myoblasts in vitro is sensitive to a donor of nitric oxide and superoxide, SIN-1, but not to nitric oxide or peroxynitrite alone.
    Lepore DA; Stewart AG; Tomasi A; Anderson RL; Hurley JV; Morrison WA
    Nitric Oxide; 1999 Aug; 3(4):273-80. PubMed ID: 10444366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of High-Throughput Method for Measurement of Vascular Nitric Oxide Generation in Microplate Reader.
    Abd El-Hay SS; Colyer CL
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28098791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery.
    MacAllister RJ; Calver AL; Riezebos J; Collier J; Vallance P
    J Pharmacol Exp Ther; 1995 Apr; 273(1):154-60. PubMed ID: 7714761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye.
    Behar-Cohen FF; Goureau O; D'Hermies F; Courtois Y
    Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1711-5. PubMed ID: 8675417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
    Spreux-Varoquaux O; Ulmer B; Cordonnier P; Forestier A; Pays M; Ducreuzet C; Advenier C
    Fundam Clin Pharmacol; 1991; 5(6):549-56. PubMed ID: 1955198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.